Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 3—March 2006

Cost-effectiveness of West Nile Virus Vaccination

Armineh Zohrabian*Comments to Author , Edward B. Hayes†, and Lyle R. Petersen†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Centers for Disease Control and Prevention, Fort Collins, Colorado, USA

Main Article

Table 3

Sensitivity of the average cost-effectiveness ratio (ACER) for input variables

Rank Input variables Regression coefficient†
1 Probability of symptomatic illness 0.65
2 Probability of infection 0.51
3 Vaccination cost 0.50
4 Probability of symptomatic illness after vaccination –0.14
5 Probability of neuroinvasive disease, given symptoms 0.05
6 Cost of lifelong disability –0.03
7 Probability of disability, given neuroinvasive disease 0.03
8 Cost of neuroinvasive disease –0.02
9 Cost of uncomplicated WNV febrile illness* –0.01
10 Cost of death (direct and indirect financial losses) –0.01
11 Probability of death, given neuroinvasive disease 0.00

*WNV, West Nile virus.
†@Risk analysis software runs a regression where the dependent variable is the output variable, i.e., ACER, and the independent variables are the input variables presented as @Risk uniform distribution functions. Each iteration represents an observation for the regression. The coefficient calculated for each input variable measures the sensitivity of the output to that particular input distribution. For example, a coefficient of 0.65 indicates that a 1–standard deviation (SD) increase in probability of symptomatic illness increases the ACER by an SD of 0.65.

Main Article

Page created: January 27, 2012
Page updated: January 27, 2012
Page reviewed: January 27, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.